Pharm Exam 3 Antiviral Drugs

30 terms by myamia505

Create a new folder

Like this study set?

Create a free Quizlet account to save it and study later.

Sign up for an account

Already have a Quizlet account? .

Create an account

Advertisement Upgrade to remove ads


-Anti-Herpes Therapy
-Mechanism of action: taken up by ALL host cells, but phosphorylated to monophosphate by virus-encoded thymidine kinase, so ONLY infected cells affected
-converted to TRIPHOSPHATE by host cell enzymes
-leads to competitive viral DNA polymerase inhibition

Acyclovir Resistance

-Absence of partial production of viral thymidine kinase
-Altered thymidine kinase specificity
-Altered viral DNA polymerase

Acyclovir pharmacokinetics

-Poor oral bioavailability, bioavailabil. decreases with increased doses
-good body fluid penetration
-topical application--> decreased effectiveness
-eliminated UNCHANGED in urine

Acyclovir adverse effects

-Nausea, diarrhea
-Renal insufficiency and neurotoxicity with IV formulation


-prodrug of acyclovir- converted rapidly and completely via enzymatic hydrolysis
-better oral bioavailability than acyclovir
-similar adverse effects to acyclovir
Clinical use:
-as effective as acyclovir for HSV
-BETTER than acyclovir for VZV treatment

Examples of anti-influenza drugs

-Amantadine (Symadine)- NO longer used due to resistance
-Rimantadine (Flumadine)- NOT used due to resistance
-Osetalmivir (Tamiflu)
-Zanamivir (Relenza)


-Inhibitor of Influenza A and B NEURAMINIDASES- causes conformational change within enzyme's active site
-RESISTANCE due to mutations of hemagglutinin or neuraminidase
- Rapid absorption and activation by esterases in GI
tract and liver
- Cleared by the kidneys
• Adverse effects
- GI upset
• Clinical use
- Prophylaxis in those who cannot receive vaccine
- Early treatment . decrease symptoms by 1-2 days


- Inhibitor of Influenza A and B neuraminidases .causing a conformational change within the enzyme's active site
• Resistance
- Mutations to hemagglutinin or neuraminidase
• Those variants have reduced infectivity and virulence
- Resistance has not been documented in immunocompetent hosts
• Pharmacokinetics
- Low oral bioavailability . available as oral inhalant
• Adverse effects
- Wheezing, Bronchospasm
• Clinical use
- Prophylaxis in those who cannot receive vaccine
- Early treatment . decrease symptoms by 1-3 days


Used for RSV Treatment and Hepatitis Tx
• Mechanism of action:
- Inhibits both RNA and DNA viruses secondary to alterations of cellular nucleotide pools and inhibits viral messenger RNA synthesis
• No documented resistance
• May decrease morbidity in some children
• Adverse effects
- Transient wheezing and rash (aerosolized)
- Increased bilirubin, anemia, and rigors (systemic)
- Teratogenic

What can be used for Anti-Hepatitis Therapy?

- Lamivudine
- Adefovir
- Entecavir
- Telbivudine
- Tenofivir
• Interferon

Interferon alfa

• Naturally occurring proteins produced by host
cells in response to viral infections

Interferon alfa-2b

• Produced by recombinant DNA technology
- Stimulates the body's immune system to fight off the virus
• Induction of gene transcription
• Inhibits cellular growth
• Alters the state of cellular differentiation
• Interferes with oncogene expression
• Alters cell surface antigen expression
• Increases phagocytic activity of macrophages
• Augments cytotoxicity of lymphocytes
• Clinical use
- Hepatitis B
- Hepatitis C
• Requires dosing adjustment in renal insufficiency
• Black Box Warning
- DC therapy if patient develops severe pulmonary symptoms, autoimmune disorders, worsening hepatic function, psychiatric symptoms, ischemia, or infectious disorders

Fusion Inhibitors (FI)

• Prevent HIV from entering healthy CD4+ cells
- Block proteins on the surface of HIV or on the
CD4+ cell by binding to glycoprotein-41
• These proteins are required for the virus to gain entry
into the cell (e.g. fuzeon)

Fusion Inhibitor Pharmacokinetics

• Twice daily subcutaneous injections
• Does NOT affect the metabolism of other antivirals requiring the CYP system
- No reported DDI
• NO dose adjustments needed for renal or mild-moderate hepatic dysfunction

How does Fusion Inhibitor Resistance develop?

• Amino acid substitutions resulting in loss of
• Give in combination with other antivirals to
decrease resistance

Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

• Incorporates into the DNA of the virus
- Must be converted to triphosphate inside host cell by host
cell kinases
- Inhibiting the replication process and terminating the DNA
- Cannot create new virus
• Some examples
- Emtricitabine
- Lamivudine
- Zidovudine
- Didanosine
- Stavudine

NRTI Pharmacokinetics

• Well absorbed
- Zidovudine- food slows absorption
- Didanosine- take 30 minutes before or 2 hours after food
- Stavudine- NOT affected by food
• Does require intracellular phosphorylation
• Renally excreted

NRTI Adverse Effects

• Anemia
• Granulocytopenia/ bone marrow suppression
• Myopathy
• Neuropathy
• Pancreatitis
• Steatosis
• lipoatrophy
• Lactic acidosis (with or without hepatomegaly)

NRTI Resistance

• Two mechanisms of resistance
- Impaired incorporation into viral DNA
- Removed from viral DNA
• Thymidine analog mutation removes NRTI from DNA .
conformational change to reverse transcriptase
- Causes a break in DNA chain . DNA unable to continue
• Mutations occur over time
- More than 1 mutation needed to cause resistance
• Except M184V mutation -> resistance with single mutation

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

• Stops HIV production within the host cell
- Binds directly onto the reverse transcriptase, preventing the conversion of RNA to DNA
• Examples
- Nevirapine
- Efavirenz
- Rilpivirine
- Delavirdine mesylate
- Etravirine

NNRTI Pharmacokinetics

• MUCH variability amongst individual NNRTIs
• Well absorbed
- NOT altered by food
• Does NOT require intracellular phosphorylation to be active
• No activity against host cell DNA polymerase
• Crosses placenta and concentrated in breast milk
• Metabolized by CYP enzymes
• Varying DDIs

NNRTI Resistance

• Highly susceptible to resistance
- Single mutation affecting binding site
• Do NOT use as monotherapy
• Cross resistance between NNRTIs

Protease Inhibitors (PIs)

• Prevent HIV from being assembled and released from the infected CD4+ cell
• Some examples
- Amprenavir
- Indinavir sulfate
- Saquinavir
- Ritonavir
- Nelfinavir

Protease Inhibitor Pharmacokinetics

• High interindividual variability
• Highly protein bound
• Hepatic clearance
• P-glycoprotein efflux pump substrate
- Limits concentration in the brain
• CYP 3A4 substrates
- Often given with low dose ritonavir

Protease Inhibitor Resistance

• Mutations in the enzymatic active site
- Multiple mutations needed for high-level resistance
• Secondary mutations distant from active site
• Resistant to 1 PI . resistance to ALL Pis
- More mutations increase likelihood of crossresistance
- Secondary resistance decreases likelihood of longterm

Integrase Inhibitors (IIs)

• Prevents the transport and attachment of
proviral DNA to host-cell chromosomes
- Inhibiting transcription of viral proteins and the assembly of virus particles
• Example
- Raltegravir (Isentress®)

Integrase Inhibitor Pharmacokinetics

• Rapid oral absorption
- Not affected by food
- Antacids decrease absorption
• Protein bound
• P-glycoprotein substrate
- Minimal CNS penetration

Integrase Inhibitor Resistance

• Mutations exist to viral integrase gene
- 2 clinical trials have demonstrated decreased

Chemokine Receptor Antagonists

• Selectively binds to a chemokine coreceptor
(CCR5) that is partly responsible for the
binding and then fusion of HIV to CD4 cells
- The interaction between CRA and coreceptor
blocks HIV interaction and inhibits fusion
• Example
- Maraviroc (Selzentry®)

Chemokine Receptor Antagonist Pharmacokinetics

• Protein bound
• Metabolized via CYP3A4
- MUST be dose adjusted when given with other inhibitors or inducers
• P-glycoprotein substrate
- Minimal CNS penetration
• Resistance has been observed
- Unknown mechanism

Please allow access to your computer’s microphone to use Voice Recording.

Having trouble? Click here for help.

We can’t access your microphone!

Click the icon above to update your browser permissions above and try again


Reload the page to try again!


Press Cmd-0 to reset your zoom

Press Ctrl-0 to reset your zoom

It looks like your browser might be zoomed in or out. Your browser needs to be zoomed to a normal size to record audio.

Please upgrade Flash or install Chrome
to use Voice Recording.

For more help, see our troubleshooting page.

Your microphone is muted

For help fixing this issue, see this FAQ.

Star this term

You can study starred terms together

NEW! Voice Recording

Create Set